Results 161 to 170 of about 60,096 (254)

Metarhizium anisopliaeMitigates the Phytotoxicity of Lead and Nanoplastics on Rice by Modifying Physiological, Transcriptomic, Metabolomic Activities, and Soil Microbiome

Advanced Science, EarlyView.
Metarhizium anisopliae alleviates the phytotoxic effects of polyethylene nanoplastics (NP) and lead (Pb) in rice by decreasing Pb uptake, restoring antioxidant and hormonal equilibrium, and promoting growth. Additionally, the fungus modifies the rhizosphere microbiota, enhancing both contaminant tolerance and plant growth, thereby effectively ...
Jing Peng, Qi Yan, Muhammad Umair Hassan, Muhammad Imran, Fasih Ullah Haider, Jianfeng Liang, Xingmin Wang, Shaukat Ali   +7 more
wiley   +1 more source

Bernard-Soulier Syndrome: Identification of a Novel GP1BB Variant in a Mauritanian Patient. [PDF]

Mol Genet Genomic Med
Salem ML, Zein E, Mohamed GS.
europepmc   +1 more source

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

Advanced Science, EarlyView.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao, Chengming Qu, Yanzhao Zhou, Xiaoqian Wang, Xiangjun Qian, Xun Chen, Feng Han, Xiaokai Zhang, Yiyi Ji, Han Li, ChengWei Ju, Peng Xia, Weiwei Tang, Hao Zhuang, Jinxue Zhou   +14 more
wiley   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

Targeting the apical domain of the transferrin receptor: Development of a new protein scaffold for cellular delivery. [PDF]

Protein Sci
Veetil AA, Sjöström DJ, Iribarren C, Mohlin C, Ambrosetti E, Bjelic S.   +5 more
europepmc   +1 more source

Dorsal Raphe VIP Neurons Are Critical for Survival‐Oriented Vigilance

Advanced Science, EarlyView.
DRNVIP neurons in mice and primates are strategically positioned to influence the central extended amygdala via feedback loops. They regulate the excitability of PKC‐δ neurons in the ovBNST and CeA through glutamate release. Their ablation heightens activity in these regions, disrupts active‐phase sleep architecture, enhances risk assessment behaviors ...
Adriane Guillaumin, Emma Perrot, Thibault Dhellemmes, Laura Boi, Daniel De Castro Medeiros, Christelle Glangetas, Sylvie Dumas, Sandra Dovero, Nathalie Biendon, Elodie Ladeveze, Maëlle Hardel, Marc Landry, Erwan Bezard, Jérôme Baufreton, Gilberto Fisone, François Georges   +15 more
wiley   +1 more source

Time‐ and dose‐related pathological changes in knee osteoarthritis rat model induced by monosodium iodoacetate

Animal Models and Experimental Medicine, EarlyView.
Time‐ and dose‐related pathological changes of knee osteoarthritis rat model induced by monosodium iodoacetate. Abstract Knee osteoarthritis (KOA) is a chronic degenerative disease. Monosodium iodoacetate (MIA) induction is the most commonly used therapeutic effect evaluation and mechanism of action research model; we observed a lack of standardization
Wei Pu, Qi Liu, Shuyan Xue, Siyuan Li, Nan Nan, Yang Liu, Huiqin Hao   +6 more
wiley   +1 more source

Multimodal Structural Characterization of SARS-CoV-2 Spike Variants: Spectroscopic and Computational Insights. [PDF]

Int J Mol Sci
Mancini T, Luchetti N, Macis S, Minicozzi V, Mosetti R, Nucara A, Lupi S, D'Arco A.   +7 more
europepmc   +1 more source

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono, Bruce A.C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source

Characterization of Novel Variants in <i>P2YRY12, GP6</i> and <i>TBXAS1</i> in Patients with Lifelong History of Bleeding. [PDF]

Biomolecules
Zamora-Cánovas A, Marín-Quílez A, Díaz-Ajenjo L, Sánchez-Fuentes A, Gómez-González PL, Crescente M, Fernández-Mosteirín N, Padilla J, González-Porras JR, Benito R, Lozano ML, Bastida JM, Rivera Pozo J.   +12 more
europepmc   +1 more source